Payment overview · 2025
General Payments
$759.10
41 reported records · 15 companies
Healthcare provider profile · identity verified
Erika Dawn Dick, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care · CHANUTE, KS · NPI 1245685403
Verified facts
What the public records show
CMS Open Payments records show Erika Dawn Dick, APRN received $759.10 in general payments during 2025 across 41 reported records.
AstraZeneca Pharmaceuticals LP accounted for 32.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $244.85 | 32.3% | 12 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $73.90 | 9.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $71.57 | 9.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $67.90 | 8.9% | 4 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $49.08 | 6.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.69 | 6.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.90 | 6.3% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $39.66 | 5.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $28.58 | 3.8% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $16.23 | 2.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.79 | 1.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.63 | 1.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.94 | 1.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.77 | 1.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.61 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $759.10 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $187.42 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $105.78 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $76.35 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $73.90 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $68.24 | 4 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $49.08 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $48.81 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $48.81 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $48.69 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $48.69 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $37.11 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.46 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $34.46 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $29.75 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 284 | 51 |
| Gabapentin | Gabapentin | 247 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 226 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 212 | 50 |
| Furosemide | Furosemide | 211 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 189 | 45 |
| Losartan Potassium | Losartan Potassium | 184 | 46 |
| Carvedilol | Carvedilol | 181 | 32 |
| Tramadol Hcl | Tramadol Hcl | 160 | 31 |
| Potassium Chloride | Potassium Chloride | 159 | 29 |
| Lisinopril | Lisinopril | 145 | 42 |
| Azithromycin | Azithromycin | 141 | 76 |
| Metoprolol Tartrate | Metoprolol Tartrate | 130 | 25 |
| Sertraline Hcl | Sertraline Hcl | 128 | 25 |
| Atorvastatin Calcium | Atorvastatin Calcium | 124 | 30 |
| Pregabalin | Pregabalin | 122 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 96 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 95 | 14 |
| Alprazolam | Alprazolam | 88 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 87 | 13 |
| Trazodone Hcl | Trazodone Hcl | 85 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 81 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 72 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 71 | 14 |
| Omeprazole | Omeprazole | 69 | 19 |
| Lorazepam | Lorazepam | 68 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 15 |
| Meloxicam | Meloxicam | 63 | 15 |
| Mupirocin | Mupirocin | 63 | 41 |
| Celecoxib | Celecoxib | 62 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 62 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 60 | 11 |
| Bumetanide | Bumetanide | 60 | 12 |
| Baclofen | Baclofen | 59 | 13 |
| Eliquis | Apixaban | 59 | suppressed |
| Fentanyl | Fentanyl | 56 | 12 |
| Spironolactone | Spironolactone | 56 | 11 |
| Cephalexin | Cephalexin | 55 | 45 |
| Methocarbamol | Methocarbamol | 55 | 21 |
| Entresto | Sacubitril/Valsartan | 52 | suppressed |
| Prednisone | Prednisone | 52 | 34 |
| Methylprednisolone | Methylprednisolone | 51 | 36 |
| Mirtazapine | Mirtazapine | 47 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 13 |
| Fluconazole | Fluconazole | 44 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | 13 |
| Linzess | Linaclotide | 44 | suppressed |
| Movantik | Naloxegol Oxalate | 44 | suppressed |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 43 | 15 |
| Metformin Hcl Er | Metformin Hcl | 41 | 13 |
| Ozempic | Semaglutide | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | suppressed |
| Famotidine | Famotidine | 40 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Simvastatin | Simvastatin | 39 | suppressed |
| Temazepam | Temazepam | 39 | suppressed |
| Naproxen | Naproxen | 37 | 13 |
| Nystatin | Nystatin | 37 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 22 |
| Metoclopramide Hcl | Metoclopramide Hcl | 36 | 11 |
| Clonazepam | Clonazepam | 35 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Risperidone | Risperidone | 35 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Metformin Hcl | Metformin Hcl | 30 | 12 |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 28 | 23 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 23 |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | 11 |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 22 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Valproic Acid | Valproic Acid | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Cimetidine | Cimetidine | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $759.10 · 41 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, BEXSERO, BREZTRI, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, Fluad, Flucelvax, GVOKE HYPOPEN, Kerendia, LEQVIO, NURTEC ODT, OTEZLA, Ozempic, PEDIARIX, PENMENVY, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, XIFAXAN | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error